European Journal of Gastroenterology & Hepatology · 2009 · 17 citations · 23 references
Veterinary MedicinePharmacologyPharmacotherapyClinical ImmunologyImmunotherapyInflammationChronic InflammationCrohn Disease PharmacotherapyGastrointestinal ImmunologyGastrointestinal InflammationInflammatory BiomarkersInflammatory Bowel DiseaseAntibodiesC-reactive Protein TestingDisease Activity MeasurementFlow Cytometry ImmunophenotypingHemoglobin LevelsInflammatory Bowel Disease Activity AssessmentInflammatory Bowel Disease TherapyPlatelet Count Monitoring
INTRODUCTION: Infliximab was launched for the treatment of Crohn's disease (CD) in 1999. We set up a follow-up protocol to meticulously study disease development with repeated infusions of infliximab. AIM: To follow the effects of infliximab treatment on disease activity, blood chemistry, quality of life, plasma nitrite, and titers of Saccharomyces cerevisiae antibodies (ASCA). METHODS: During 1999-2008, CD patients were monitored for disease activity by Harvey-Bradshaw index, blood chemistry with hemoglobin, albumin, C-reactive protein, platelet count, leukocyte count and creatinine, quality of life by the Short Health Scale, and plasma nitrite. During the first year of treatment, follow-up was done repeatedly before and 1 week after each infusion and thereafter every year before the last infusion for 5 years. ASCA was analyzed by flow cytometry with fluorescein isothiocyanate-labelled antibodies. RESULTS: A total of 1061 infusions were given to 103 patients; 92 responders and 11 nonresponders. Responders were further monitored and Harvey-Bradshaw index decreased with infusions during the first year of treatment (P < 0.0001), whereas hemoglobin (P < 0.01) and albumin (P <0.001) increased, C-reactive protein (P < 0.01) decreased, platelets (P <0.001) increased, and leukocytes (P< 0.01) decreased. Creatinine was not affected. Short Health Scale (questions analyzed separately) decreased (P < 0.0001), and nitrite (P < 0.001) increased. During the next 4 years the improved values remained stable. Adverse effects were noted among 32% of the patients; local circulatory reactions being most common. No correlation between ASCA titers and inflammatory activity or infliximab treatment was found. CONCLUSION: Infliximab treatment is highly effective in responders and maintains symptomatic improvement and low inflammatory activity over years in CD patients.
23
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Richard F. Harvey, J.M. Bradshaw · The Lancet · 1980 · 3K citations
Long-Term Evolution of Disease Behavior of Crohn's Disease
Jacques Cosnes, Stéphane Cattan, Antoine Blain et al. · Inflammatory Bowel Diseases · 2002 · 1.4K citations · Full text